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Abstract
Background: Pre-operative chemoradiotherapy (CRT) for MRI-defined, locally advanced rectal cancer is primarily
intended to reduce local recurrence rates by downstaging tumours, enabling an improved likelihood of curative
resection. However, in a subset of patients complete tumour regression occurs implying that no viable tumour is
present within the surgical specimen. This raises the possibility that surgery may have been avoided. It is also
recognised that response to CRT is a key determinant of prognosis. Recent radiological advances enable this
response to be assessed pre-operatively using the MRI tumour regression grade (mrTRG). Potentially, this allows
modification of the baseline MRI-derived treatment strategy. Hence, in a ‘good’ mrTRG responder, with little or no
evidence of tumour, surgery may be deferred. Conversely, a ‘poor response’ identifies an adverse prognostic group
which may benefit from additional pre-operative therapy.
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Methods/design: TRIGGER is a multicentre, open, interventional, randomised control feasibility study with an
embedded phase III design. Patients with MRI-defined, locally advanced rectal adenocarcinoma deemed to require
CRT will be eligible for recruitment. During CRT, patients will be randomised (1:2) between conventional
management, according to baseline MRI, versus mrTRG-directed management. The primary endpoint of the
feasibility phase is to assess the rate of patient recruitment and randomisation. Secondary endpoints include the
rate of unit recruitment, acute drug toxicity, reproducibility of mrTRG reporting, surgical morbidity, pathological
circumferential resection margin involvement, pathology regression grade, residual tumour cell density and
surgical/specimen quality rates. The phase III trial will focus on long-term safety, regrowth rates, oncological survival
analysis, quality of life and health economics analysis.
Discussion: The TRIGGER trial aims to determine whether patients with locally advanced rectal cancer can be
recruited and subsequently randomised into a control trial that offers MRI-directed patient management according
to radiological response to CRT (mrTRG). The feasibility study will inform a phase III trial design investigating
stratified treatment of good and poor responders according to 3-year disease-free survival, colostomy-free survival
as well as an increase in cases managed without a major resection.
Trial registration: ClinicalTrials.gov, ID: NCT02704520. Registered on 5 February 2016.
Keywords: Randomised control trial, Chemoradiotherapy, Rectal cancer, mrTRG, Complete response, Tumour
regression, Tumour cell density
Background
Currently, 45–55% of rectal cancer patients receive
pre-operative chemoradiotherapy (CRT) for locally ad-
vanced disease at presentation. Pre-operative CRT is
given in order to downstage the tumour. It has three
potential benefits in high-risk rectal cancers that re-
spond to treatment: an increased likelihood of a clear
circumferential resection margin (CRM); less radical
surgery than was initially planned on the baseline sta-
ging magnetic resonance imaging (MRI) [1]; and in a
small subset of patients in whom there is no clinical
or radiological evidence of tumour, the option of de-
ferral of surgery [2, 3]. However, the response to
treatment is highly variable, with up to 30% of pa-
tients achieving a complete or near-complete response
as judged by pathological tumour regression grade
(pTRG). Prognostically, a good pTRG is associated
with significantly lower local recurrence, distant meta-
static rates and with higher overall survival compared
with a poor pTRG [4, 5].
The need for a validated means of assessing re-
sponse to treatment is widely accepted [6] but there
has been no reliable method of assessing this re-
sponse in the pre-operative setting to date. Therefore,
the current consensus is that the baseline MRI
staging should be the standard of care that is used to
define the plane of surgery, regardless of any assess-
ment of treatment response [7]. Recently, a 5-point
MRI tumour regression grade (mrTRG), which most
closely resembles the Mandard pTRG system [8], has
been developed [9]. The basic principle of both grad-
ing systems relates to the ratio of tumour to fibrosis
following CRT (Table 1). Patients with a poor CRT
response have a 5-year overall survival of 27% versus
72% (p = 0.001) for a good CRT response [10]. This
novel imaging biomarker has been reliable and repro-
ducible between multiple independent radiologists,
and validated against both pathology and survival
outcomes [10–12]. However, there is currently insuffi-
cient evidence that this information can be safely
used to alter treatment decisions.
The ‘good-response’ group (mrTRG I and II)
The complications of surgery can be considerable.
The 90-day mortality rate from a major bowel resec-
tion is 3–6% [13], significant morbidity is frequent
and long-term functional impairment is common,
even in the presence of restorative surgery [14–16].
When a pathological complete response (pCR) to
CRT occurs, with no residual cancer identified, this
raises the possibility that the risks of surgery may
have been avoided by watchful waiting or deferral of
surgery [17]. Pioneered by Professor Angelita Habr-
Gama, several cohorts have demonstrated this to be
feasible and safe; avoiding radical surgery by close
surveillance of selected patients in whom there is
clinical disappearance of the tumour following CRT
Table 1 Magnetic resonance imaging tumour regression grade
(mrTRG)
mrTRG 1 – Complete radiological response (linear scar only)
mrTRG 2 – Good response (dense fibrosis, no obvious tumour signal)
mrTRG 3 – Moderate response (>50% fibrosis and visible intermediate signal)
mrTRG 4 – Slight response (mostly tumour)
mrTRG 5 – No response/regrowth of tumour
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[2, 3, 18]. Termed as a clinical complete response
(cCR), the combination of digital rectal examination,
endoscopy and imaging are used to define and moni-
tor patients under a deferral of surgery protocol as a
surrogate for a pCR, thereby avoiding radical surgery
[19–21]. However, current techniques for assessing a
cCR are unreliable, and up to two thirds of patients
are not identified pre-operatively [22–25]. By using
the novel mrTRG biomarker prospectively in a rando-
mised controlled study, it may be possible to
determine the precise safety of this approach, whilst
increasing the proportion of cCR patients identified
using an objective and validated tool.
A good tumour response on post-CRT MRI (mrTRG I
and II) may enable a nonoperative approach to rectal
cancer. Consequently, patients may have a reduced
overall morbidity and mortality [26], as well as an
improvement in quality of life (QoL).
The ‘poor-response’ group (mrTRG III–V)
The TRIGGER trial will offer poor responders con-
solidation therapy using a fluorouracil (5-FU)-based
regimen combined with oxaliplatin (infusional 5-FU
or capecitabine with oxaliplatin, FOLFOX or
CAPOX). These regimens have been shown to be ef-
fective systemic treatments for colorectal malignancy
and they are recommended by most international
guidelines [27, 28], usually in the post-operative set-
ting. However, a prospective study by Garcia-Aguilar
et al. found that FOLFOX can be used as pre-
operative consolidation therapy, along with conven-
tional CRT, without evidence of additional toxicity
[29]. In the SOCRATES trial, patients received a simi-
lar regimen of radiotherapy and oxaliplatin; however,
capecitabine (the 5-FU oral prodrug) was used [30].
The CAPOX treatment regime was offered to patients
with locally advanced rectal cancer, 82 of the 83
patients enrolled into the trial completed the pre-
operative CAPOX regimen and 78 patients proceeded
to surgery. Similar compliance rates were seen with
pre-operative CAPOX-RT in a German study, where
compliance rates were 96% [31]. In TRIGGER, ‘poor
responders’ (mrTRG III–V) will be offered systemic
oxaliplatin and either 5-FU or capecitabine pre-opera-
tively. In this high-risk subgroup of patients, the earl-
ier introduction of systemic therapy appears not only
to improve compliance but also tumour response
rates and the rates of distant metastatic disease [32].
Methods/design
Trial overview
The TRIGGER trial is a multicentre, open, randomised
control trial (Additional file 1). Randomisation is 2:1 in
favour of mrTRG-directed management. We anticipate
that 30 centres will recruit to the study. The phase III
primary endpoints will compare outcomes by intention-
to-treat analysis between the control arm and the inter-
ventional arm. There are two prospective subtrials, the
first involves the ‘good-response’ group and the second
involves the ‘poor-response’ group. The trial flow chart
is shown in Fig. 1 (Additional files 2 and 3). The trial has
been developed in accordance with Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) guidelines (Additional file 4).
Study population and eligibility criteria
Eligible patients are 18 years or older at the time of
diagnosis, able to give informed consent, and have a
biopsy-confirmed adenocarcinoma 0–15 cm from the
anal verge measured on MRI or rigid sigmoidoscopy.
The initial staging MRI must indicate locally
advanced rectal carcinoma, defined here as: mrCRM
unsafe, ≥mrT3c (>5 mm beyond muscularis propria),
mrN1c (extramural tumour deposit not typical of
lymph nodes) or MRI-assessed evidence of extramural
venous invasion (mrEMVI)-positive disease (extra-
mural venous invasion on MRI). The patient must be
deemed to require chemoradiotherapy and scheduled
to receive 45 Gy–55 Gy long-course radiotherapy.
Patients will be ineligible if there is evidence of
distant metastatic disease, including resectable liver
metastases; MRI contraindications; intolerance or
contraindication to planned chemoradiotherapy
(CRT); receive alternative cytotoxic or investigational
drug treatment outside of protocol stipulation; preg-
nancy; breastfeeding; other malignant disease within
the preceding 5 years with the exception of non-
melanomatous skin cancer, carcinoma in situ and
early stage disease with <5% recurrence risk. Some
centres report the controversial practice of offering
CRT to early stage rectal cancer patients with the
specific intention of avoiding an APE by achieving a
cCR [20]. Only patients with locally advanced disease
are eligible for TRIGGER because the multi-European
centre low rectal cancer study (MERCURY II) found
that patients with early stage low rectal cancer
(cancer that did not breach the CRM or low rectal
plane on MRI) were able to undergo a restorative re-
section the majority of the time (108/166 – 65%)
[33]. Without radiotherapy this group reported a
pCRM rate of 2% and these patients avoided the
morbidity and functional impairment that is associ-
ated with radiotherapy.
This is a multicentre study and currently seven trials
units are open to recruitment; we anticipate this will be
sufficient to deliver the feasibility study. A further 20
centres are undergoing the trials registration and
quality assurance process with a view to participating in
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feasibility and/or the phase III trial. Participating cen-
tres must have an established multidisciplinary team
(MDT) that includes a minimum of one oncologist, one
histopathologist, one radiologist and one surgeon, and
be able to accommodate and deliver all aspects of the
protocol, including patient follow-up, particularly the
follow-up requirements for safe deferral of surgery. The
centre is required to meet eligibility criteria and trial
conduct must comply with the protocol as agreed by
the sponsor, the Medicines and Healthcare products
Regulatory Agency (MHRA) and the Multicentre Eth-
ical Committee (MREC). Trial centres will encompass
both teaching and district general hospitals to enhance
generalisability.
Study objectives
Feasibility study objectives
 Patient recruitment – the number of eligible
patients willing to enter the study, and the rate of
concordance with the allocated treatment plan
 Centre recruitment – acceptability of the trial
concept and the protocol to each unit as well as the
ability of radiologists to reliably assess response
(agreement with central radiologist measured using
a training set with kappa >0.7)
 Evaluate the reproducibility of mrTRG by assessing
the strength of the agreement between the
recruiting radiologists and the central radiologist
Fig. 1 a Scheduled to receive 45 Gy–55 Gy long-course radiotherapy. b Treatment decision should be made prior to registration (planned choice
is a randomisation stratification variable). Medical oncologist may choose to use CAPOX or FOLFOX, or single-agent capecitabine or 5-FU if con-
comitant use of oxaliplatin is contraindicated. c Patient defers surgery then the remaining 12 weeks of chemotherapy should be given as soon as
possible following the repeat magnetic resonance imaging (MRI) scan and multidisciplinary team (MDT) meeting
Battersby et al. Trials  (2017) 18:394 Page 4 of 14
 Assess the clinical, radiological response rate in the
control versus intervention arm. Pathological
response rate will also be reported and compared
when possible
 Evaluate safety by assessing acute drug toxicity and
30-day surgical morbidity
 Compare the control arm versus the intervention
arm in terms of pCRM involvement and specimen
quality as a proxy for quality of surgery (quality
graded by plane of surgery as: complete clinical
response (no specimen), mesorectal, intramesorectal,
and muscularis propria). The assessment will include
patients who undergo surgery for tumour regrowth
following initial management with deferral of
surgery
Phase III study objectives
 The primary objective of the phase III trial will be to
compare 3-year disease-free survival (DFS) in the
control arm versus the mrTRG-directed
management arm
 Overall survival (OS), colostomy-free survival (CFS),
distant (DR) and local recurrence (LR) in the control
arm versus the mrTRG-directed management arm,
and tumour regrowth rates in patients treated with
deferral of surgery
 QoL comparison
 Cost-utility analysis
Sample size
The feasibility study is designed to determine whether
proceeding to a phase III study is realistic. Using the
phase III primary endpoint of 3-year DFS, an expected
improvement in DFS for the intervention group by
intention-to-treat analysis would be 82% from 74% (i.e. a
hazard ratio of 0.66) with 80% power and a 5% two-sided
level of statistical significance. This would require 633
patients: 422 in the intervention arm and 211 in the
control arm based on a 2:1 allocation ratio to be re-
cruited over 3 to 5 years with at least 3 years’ follow-up.
Hence, in order for the phase III trial to be viable, re-
cruitment rates of at least 5–6 per month (to recruit 633
patients in 5 years) and, ideally, 11 per month (to recruit
633 patients in 3 years) should be achievable. The feasi-
bility study was, therefore, designed to test the null hy-
pothesis that the maximum possible recruitment rate is
no more than 6 per month, and power calculations were
performed under the assumption that the a rate of 11
per month can be achieved. The type-I error significance
threshold (alpha) was set at 0.1, with a type-II error (β)
at 5% with the resulting power (1 − β) at 95% (calculated
using simulation). In order to allow for a set-up period
of 6 months we will recruit for a total of 10 months,
with recruitment rates for the last 4 months used to test
the primary hypothesis. Thus, during the final 4 months
recruitment is expected to be 11 patients per month and
can be no less than 6 patients per month (6 per month
results in 5.5 years total recruitment time).
Randomisation
Patients identified at the MDT as potentially eligible for
TRIGGER are invited and may consent to register prior
to CRT. Basic demographic and clinical information will
be collected. During CRT, eligible patients are then con-
sidered for randomisation. Registered patients who are
not randomised are retained along with the reason for
nonrandomisation, so that the causes for ‘drop-out’ and
estimates of generalisability can be established.
Randomisation is performed centrally, at the TRIGGER
trial office, by a computer-based randomisation algorithm.
Patients are randomised 2:1 in favour of mrTRG-directed
management (interventional arm) over best current man-
agement (control arm) based on the index staging MRI.
To avoid chance imbalance in the two arms, randomisa-
tion will factor-in stratification variables: recruiting site,
mrEMVI status, tumour height, and planned choice of
systemic chemotherapy.
Following randomisation, the radiologist from the
recruiting centre will report the mrTRG for the
intervention arm but not for the control arm. It is
not possible to blind the patient, radiologist, surgeon
or pathologist, but these assigned members of the
MDT will be trained to manage patients according to
the TRIGGER protocol (v5.0) and to prospectively
proforma report findings. To further enhance the
quality, reliability and reproducibility of the data the
radiologists and pathologists will centrally review
image quality, surgical specimen quality and patho-
logical tumour regression.
Intervention
The intervention in this study results from mrTRG-
directed management. To report the mrTRG, the base-
line and post-treatment MRI scans will be reported
according to standardised proformas and the following
imaging standards are required:
 Positioning and patient preparation – buscopan 20
mg (intra-muscularly) to be given, or other suitable
antispasmodic agents according to local protocol.
Superior saturation bands/REST slabs for adequate
abdominal motion suppression and anterior SAT
band to be used in conjunction with AP-phase
encoding direction to reduce image degradation
due to abdominal wall motion. Firm surface coil
placement – lower edge of coil 10 cm below sym-
physis pubis
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 T2-weighted images – TR >3500 ms, TE >80 ms
 Adequate signal to noise – at least four acquisitions
and 6 min per sequence
 Adequately high resolution scans – field of view and
matrix parameters should not exceed a pixel size of
0.6 mm × 0.6 mm; either 200 mm × 200 mm with
384 × 384 matrix or 160 mm × 160 mm with a
256 × matrix. Slice-thickness 3 mm giving a 0.6
mm × 0.6 mm × 3 mm= 1.1-mm3 voxel
 Adequate coverage – high-resolution scans extend
to at least 5 cm above the top of tumour. Any
discontinuous deposits seen on sagittal view are
also covered on the high resolution axial views
The post-CRT MRI should be performed within
4–6 weeks, and no later than 10 weeks of CRT
completion.
Control Arm
The flow chart for the control group is shown
in Fig. 1. The mrTRG is not reported for the control
arm and surgery is performed within 6–12 weeks
from CRT completion according to the baseline MRI
staging. The follow-up and Clinical Report Form
(CRF) assessment schedule is summarised in
Table 2.
Table 2 Assessment schedule summary: control arm
Control arm Registration
period
Intervention phase Annual
follow-up
Disease
statusg
Visit type Prior to
patient
entry
Registration Randomisation
(baseline)
Post
CRT
MDT surgery Surgical
follow-up
Adjuvant chemotherapy for
24 weeks
12 24 36 60
Timelines ≤4 weeks
prior to CRT
During CRT 4–6
weeks
post
CRT
6–12
weeks
post CRT
6 weeks
post
surgery
Toxicity assessed at
end of each chemotherapy
cycle
Months from end
of CRT
Informed consenta X X
Check eligibility
criteria
X X
Diagnosis, history
and clinical
assessment
X
Randomisation X
Quality of life X X X
Chemoradiotherapy X
Blood sampleb X X X X X X
Baseline MRI X
Restaging MRIc X
Surgery X
Surgical morbidityf X X
Pathologyd X
Chemotherapy X end of each cycle
Toxicity assessment X end of each cycle X
Annual follow-up X X X X X
Adverse eventse X X X X end of each cycle
Concurrent
medications
X X X X X X end of each cycle
CRT pre-operative chemoradiotherapy, MDT multidisciplinary team, MRI magnetic resonance imaging
The X also denotes that Clinical Report Forms (CRFs) need completing
aEligible subjects will be asked to provide written informed consent at registration and before randomisation
bIf patient has consented to additional blood sample collection for research
cThe post-CRT MRI should to be performed within 4–6 weeks (maximum of 10 weeks) from completion of CRT
dResected specimen will be prepared and evaluated using a standardised protocol
eAll adverse events will be recorded from the date the post-CRT MRI scan is performed until 30 days after the last dose of chemotherapy is administered during
the intervention phase of the trial
fBoth early (4–6 weeks) and late surgical complications (at 12 months) will be recorded
gDisease status at 5 years (does not require clinic visit): alive without metastatic or recurrent disease, alive with metastatic and/or recurrent disease (date
diagnosed), dead (date of death)
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Experimental intervention – good response (mrTRG I and II)
The flow chart for the good-response group of the
intervention arm is shown in Fig. 1. This group has
been randomised to mrTRG-directed management
and, where the post-treatment MRI suggests a good
response (mrTRG I or II), the option of deferral of
surgery is discussed with the patient and intensive ac-
tive monitoring is undertaken. This will involve a
combination of clinical assessments, imaging surveil-
lance, and endoscopy at regular intervals, as per the
schedule shown in Table 3. These patients will subse-
quently receive 24 weeks of chemotherapy (eight cy-
cles of CAPOX or 12 cycles of FOLFOX) and this
should start within 12 weeks of CRT completion. The
follow-up and CRF assessment schedule is sum-
marised in Table 4.
Detection of local regrowth
A regrowth is a defined as recorded evidence of dis-
ease at the site of the primary tumour in a patient
with previous investigations suggesting an apparent
cCR. Patients with evidence of clinical or radiological
local regrowth or pelvic relapse must be treated at
least as urgently as a primary rectal cancer by the
surgical team (Fig. 2). A biopsy identifying regrowth
of adenocarcinoma should ideally be sought before
planning surgical intervention and, in equivocal cases,
a MDT discussion should take place to decide on the
best course of action. If a patient refuses, or is not fit
for, surgery then a ‘Discontinuation of Trial
Treatment Form’ should be completed and the patient
followed up unless they withdraw consent to further
data collection. Follow-up will also monitor for unsal-
vageable regrowth – a tumour with radiological evi-
dence of a good response that progresses following
initial deferral of surgery management. The extent of
progression means that the patient develops inoper-
able disease or pCRM involvement.
Experimental intervention – poor response (mrTRG III–V)
The flow chart for the poor response group of the
intervention arm is shown in Fig. 1. This group has
been randomised to mrTRG-directed management
and the post-treatment MRI suggests a poor response
(mrTRG III–V). The option of intensified additional
chemotherapy is discussed with the patient, and if the
patient consents, 12 weeks of chemotherapy will be
given (four cycles of CAPOX or six cycles of
FOLFOX); this should start within 12 weeks of CRT
completion. Following the completion of 12 weeks of
chemotherapy, a repeat MRI should be performed 4–
6 weeks later and mrTRG reported again. If this MRI
suggests a good response (mrTRG I or II), deferral of
surgery can be discussed; otherwise, the patient
Table 3 Deferral of surgery follow-up protocol
Time line from end of CRT Visit window Clinic OPAb PROMc Scans Endoscopy
6 monthsa,d ±1 month X MRI Flex sig
9 monthsd ± 1 month X MRI Flex sig
1 yeard ± 1 month X EORTC QLQ-C30, LARS, EQ-5D MRI
CT
Colonoscopy
1 year 3 months ± 1 month X
1 year 6 monthsd ± 1 month X MRI Flex sig
1 year 9 months ± 1 month X
2 yearse ± 1 month X MRI
CT
Flex sig
2 years 6 monthse ± 1 month X
3 yearsd ± 2 months X EORTC QLQ-C30, LARS, EQ-5D MRI
CT
Flex sig
3 years 6 months ± 2 months X
4 yearsd ± 2 months X MRI Flex sig
4 years 6 months ± 2 months X
5 yearsd ± 3 months X EORTC QLQ-C30, LARS, EQ-5D MRI Colonoscopy
aThis visit should take place once the patient has completed chemotherapy. It is recommended that a computed tomography (CT) scan is also performed following
the completion of chemotherapy as is usual practice
bEach clinic outpatient appointment (OPA) should include a digital rectal exam and CEA (tumour marker) blood test
cQuality of life Case Record Form (CRF): EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30, v3;
LARS, Low Anterior Resection Syndrome Score; EQ-5D, EuroQol Group five dimensions Health Questionnaire
dIf patient has consented to the additional blood sample collection for research (circulating tumour DNA and markers of cell proliferation and apoptosis) then
samples collected during the clinic outpatient appointment, ideally at the same time as the routine blood tests are performed
CRT pre-operative chemoradiotherapy, Flex sig flexible sigmoidoscopy, PROM patient-reported outcome measure
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should proceed to surgery according to the baseline
and post-treatment imaging. The follow-up and CRF
assessment schedule is summarised in Table 5. The
SPIRIT diagram for both randomisation arms and
intervention arm sub-groups is shown in Table 6.
Translational studies
The molecular determinants of response to CRT in
rectal cancer are currently poorly understood. The
TRIGGER trial represents a unique opportunity to
undertake comprehensive ‘genotype-phenotype’ com-
parisons as this will enable validation studies for can-
didate biomarkers from preliminary studies [34].
Patients will be asked to consent to the transfer of
their tumour and normal mucosal tissue from the
pre-treatment biopsy and post-treatment resection
specimen to the central laboratory (Institute of
Cancer Research/Royal Marsden BRC, UK), and the
collection of an additional research blood samples.
Slides will be assessed for pathological tumour
regression and tumour cell density centrally (Leeds
Institute of Cancer and Pathology, UK) and tissue will
also be assessed in collaborating centres (Radboud
University Nijmegen, Netherlands and University of
Southampton, UK).
Patient-reported outcome measures (PROMs)
The QoL aspect will be evaluated through validated
self-administered PROMs questionnaires at 12 and 36
months post completion of CRT. All patients will be
requested to fill out a European Organisation for
Research and Treatment of Cancer Quality of Life
Questionnaire-core 30, v3 (EORTC QLQ-C30) [35]
and the EuroQol Group five dimensions Health
Fig. 2 Flow chart for the management of tumour regrowth after initial deferral of surgery
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Table 6 SPIRIT diagram for both randomisation arms and intervention arm sub-groups
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Questionnaire (EQ-5D) [36] to derive a global health-
related QoL assessment [37]. In addition to this,
bowel function will be assessed through the Low
Anterior Resection Syndrome (LARS) questionnaire
and will be reported according to the severity of
bowel dysfunction, as has been reported previously [38].
Withdrawals
By consenting to the trial, patients will understand
that they are consenting to follow-up, data collection,
additional MRI scans, additional endoscopy and the
collection of biological samples for future research.
Selective agreement to these investigations will be
treated as a partial withdrawal. Patients have the right
to withdraw partially or fully from the study at any
time and for any reason without prejudice to their
future medical care. Patients’ decision for full
withdrawal must be recorded in hospital records and
a withdrawal CRF should be completed, including
primary reason for withdrawal. No further CRFs,
except for serious adverse event data, should be com-
pleted. Partial withdrawal of consent means that the
patient does not wish any further trial treatment but
is still willing to provide on-going observational data
by continuing with study follow-up. A patient may
discontinue trial treatment whenever the treatment is
no longer in the patient’s best interests, the reasons
for doing so should be clearly recorded.
Safety evaluation and reporting of adverse events
The investigator is responsible for ensuring that all
adverse events, adverse reactions, unexpected adverse
reactions (UARs), suspected unexpected serious ad-
verse reactions (SUSARs), and serious adverse events
(SAEs) observed by the investigator or reported by
patients from the date of the post-CRT MRI until 30
days after the last dose of chemotherapy is adminis-
tered are properly captured in the patients’ medical
records. Adverse events occurring in all arms of the
trial should be reported with the same diligence so
that bias is not introduced to the apparent incidence
of adverse events observed in either arm. The Trial
Management Group (TMG) will review all events and
reactions. All SAEs will be reported to the TMG ap-
proximately 6-monthly and to the Data Monitoring
and Ethics Committee (DMEC) annually.
Discussion
The current consensus is to plan treatment for rectal
cancer using baseline MRI staging [7]. However, this
position is changing and some authors believe that
there is a moral imperative to inform patients if they
have had a cCR following CRT, with a view to offer-
ing these patients deferral of surgery [39, 40]. With
the accurate detection and surveillance of a cCR still
problematic, there is a need to develop validated and
reproducible means of assessing response to CRT in
rectal cancer in a trial setting. The TRIGGER trial is
designed to prospectively evaluate mrTRG as a novel
biomarker for assessing CRT response. It is the first
randomised control trial in rectal cancer to stratify
management according to the grade of response to
pre-operative CRT, and thus tailor treatment to
achieve optimal oncological and functional outcomes.
Initially, the feasibility study will assess the ability to
recruit and randomise patients to deliver a mrTRG-
directed management. If this is successful, we intend
to perform a phase III trial that will assess whether
mrTRG can improve QoL and DFS through a perso-
nalised dual management approach; ‘poor responders’
will be offered additional treatment to enable further
downstaging and early treatment of systemic relapse
risk, and ‘good responders’ will be offered deferral of
surgery, potentially avoiding the morbidity and mor-
tality of surgery.
Trial status
The TRIGGER trial is open in the feasibility phase, and
at the time of submission 20 patients from three centres
have been recruited.
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